Entrada Therapeutics has officially launched clinical trials in Europe for its innovative exon skipping therapies targeting Exon 44 and Exon 45—marking a significant milestone in the treatment of Duchenne muscular dystrophy (DMD).
These investigational therapies are designed to address specific genetic mutations in DMD patients, with the goal of restoring dystrophin production and improving clinical outcomes. The start of these trials highlights Entrada’s commitment to advancing precision genetic medicine and expanding global access to novel treatments for rare neuromuscular diseases. – Read More: What is Exon Skipping and How does it Work? –
Table of Contents
Entrada Exon 44 Skipping – NCT07037862 –
This is a study of the investigational medicine ENTR-601-44 in participants who have Duchenne muscular dystrophy (DMD), a rare genetic condition.
Study Start (Estimated): 2025-06-30
Primary Completion (Estimated): 2029-03-28
Study Completion (Estimated): 2029-03-28
Number of Participants (Estimated): 24
Locations: Belgium, Italy, Spain, United Kingdom.
Ages Eligible for Study: 4 Years to 20 Years (Child, Adult)
Principal inclusion and exclusion criteria. – NCT07037862 –
Entrada Exon 45 Skipping – NCT07038824 –
This is a study of the investigational medicine ENTR-601-45 in participants who have Duchenne muscular dystrophy (DMD), a rare genetic condition.
Study Start (Estimated): 2025-09-30
Primary Completion (Estimated): 2029-03-01
Study Completion (Estimated): 2029-03-01
Number of Participants (Estimated): 24
Locations: Belgium, Italy, Netherlands, Spain, United Kingdom.
Ages Eligible for Study: 4 Years to 20 Years (Child, Adult)
Principal inclusion and exclusion criteria. – NCT07038824 –
Read more about Entrada Therapeutics.
Dear Clinical Trial Team,
I am writing as the parent of a 14-year-old boy who has been diagnosed with Duchenne Muscular Dystrophy (DMD). His condition has been genetically confirmed and is amenable to exon 44–targeted therapies.
We would like to express our strong interest in participating in clinical trials in Europe that are relevant to his mutation and age group. We are particularly interested in studies focused on exon-skipping, gene-based, or disease-modifying therapies, should he meet the eligibility criteria.
We are based in Latvia and are willing to travel within Europe if participation is possible. All required medical documentation, including genetic reports and clinical assessments, can be provided upon request.
Thank you very much for your time, your work, and your commitment to improving the lives of patients with Duchenne muscular dystrophy. We would sincerely appreciate any guidance or updates you can share with us.